<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694135</url>
  </required_header>
  <id_info>
    <org_study_id>EGP-437-001</org_study_id>
    <nct_id>NCT00694135</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized, Double-Masked, Safety, Tolerability and Efficacy Study of Four Iontophoretic Doses of Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious Anterior Segment Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyegate Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyegate Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define a safe and effective dose of iontophoretic delivery of
      dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in
      patients with non-infectious anterior segment uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-masked, parallel group, dose-comparison, exploratory study of
      four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in
      patients with non-infectious anterior segment uveitis. The current study will evaluate the
      safety, tolerability, and efficacy of this technology at the four dose levels to determine a
      safe effective dose appropriate for future trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with an ACC score of zero at Days 14 and 28</measure>
    <time_frame>Prospective study, subjects followed for 28 days</time_frame>
    <description>Proportion of subjects with an anterior chamber cell (ACC) score of zero at Days 14 and 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ACC score of zero</measure>
    <time_frame>Prospective study, subjects followed for 28 days</time_frame>
    <description>Time to anterior chamber cell score of zero</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a reduction of one full ACC score or more from baseline at Day 28</measure>
    <time_frame>Prospective study, subjects followed for 28 days</time_frame>
    <description>Proportion of subjects with a reduction of one full anterior chamber cell score or more (≥ 0.5 decrease) from baseline at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ACC score at Day 28</measure>
    <time_frame>Prospective study, subjects followed for 28 days</time_frame>
    <description>Change from baseline in anterior chamber cell score at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Prospective study, subjects followed for 28 days</time_frame>
    <description>Treatment emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Uveitis, Anterior</condition>
  <arm_group>
    <arm_group_label>EGP-437 1.6 mA-min at 0.4 mA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGP-437 4.8 mA-min at 1.2 mA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGP-437 10.0 mA-min at 2.5 mA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGP-437 14.0 mA-min at 3.5 mA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGP-437 1.6 mA-min at 0.4 with EyeGate® II System</intervention_name>
    <description>Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System</description>
    <arm_group_label>EGP-437 1.6 mA-min at 0.4 mA</arm_group_label>
    <other_name>Dexamethasone Phosphate Ophthalmic Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System</intervention_name>
    <description>Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System</description>
    <arm_group_label>EGP-437 4.8 mA-min at 1.2 mA</arm_group_label>
    <other_name>Dexamethasone Phosphate Ophthalmic Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System</intervention_name>
    <description>Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System</description>
    <arm_group_label>EGP-437 10.0 mA-min at 2.5 mA</arm_group_label>
    <other_name>Dexamethasone Phosphate Ophthalmic Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System</intervention_name>
    <description>Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System</description>
    <arm_group_label>EGP-437 14.0 mA-min at 3.5 mA</arm_group_label>
    <other_name>Dexamethasone Phosphate Ophthalmic Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Non-infectious anterior uveitis

        Exclusion Criteria:

          -  Uveitis of infectious etiology

          -  Previous anterior uveitis episode ≤ 4 weeks prior to baseline

          -  Intraocular pressure (IOP) ≥ 25 mmHg at baseline, a history of glaucoma, and/or
             patients who require ocular anti-hypertensive medications

          -  Topical corticosteroid treatment in either eye &lt; 48 hours prior to baseline

          -  Oral corticosteroid or intraorbital corticosteroid treatment in either eye &lt; 2 weeks
             prior to baseline

          -  Active intermediate or posterior uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Stephen Foster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye Research and Surgery Institution</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Raizman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye Research and Surgery Institution</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care Ltd.</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye &amp; Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Services University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania College of Optometry</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <zip>19027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institue</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johns Medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vittala International Institute of Ophthalmology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Nethralaya</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. M. Joshi Eye Institute</name>
      <address>
        <city>Hubli</city>
        <state>Karnataka</state>
        <zip>580 021</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College and Hospital</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <disposition_first_submitted>August 20, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 25, 2010</disposition_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stephen From, President and Chief Executive Officer</name_title>
    <organization>Eyegate Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Iontophoresis</keyword>
  <keyword>Non-Infectious Acute Anterior Segment Uveitis</keyword>
  <keyword>Ophthalmology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

